Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)
2015-005346-58Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tacrolimus in kidney allograft rejection, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Composite efficacy failure at 12 months. Started Aug 2016; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2015-005346-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005346-58.